BioAtla, Inc.

BCABNASDAQHealthcare

$0.13-0.00(-3.12%)

$0.1252-Week Range$1.43

Mkt Cap$8M

P/E—

EPS—

Div Yield—

Volume1.1M

Monitoring…

BioAtla, Inc. (BCAB) Overview

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc. operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BCAB.

Healthcare Earnings History Insider Trading

Pulse Score

D+48.5/100

Value

11/20

Growth

11/20

Health

8/20

Momentum

8.5/20

Sentiment

10/20

AI Quick Take

AI analysis is being generated. Visit the AI Intel tab for detailed analysis.

Price Trend (30D)

52W Low: $0.1252W High: $1.43

Analyst Consensus

Buy 6Hold 1Sell 0

Target: $5.00(+3734.4%)

Earnings Track Record

May 26

Miss +0.0%

Mar 26

Beat +33.3%

Nov 25

Beat +12.9%

Aug 25

Miss -6.9%

Latest Signals

Sievers sold 240K shares

Mar 10

SHORT sold 430K shares

Mar 11

How Much Would You Have if You Had Invested $2,000...

17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

18h ago

Key Statistics

Market Cap

$7.7M

P/E Ratio

-0.6

EPS

$-0.16

Volume

1.1M

Avg Volume

—

Open

$0.14

Prev. Close

$0.13

Day Range

$0.13 - $0.14

50-Day Avg

$0.19

200-Day Avg

$0.49

52W High

$1.43

52W Low

$0.12

$0.1252-Week Range$1.43

Price Performance

-3.1%

-19.0%

-22.3%

-69.3%

-81.2%

YTD

-75.6%

-55.0%

-95.7%

-99.7%

Growth Rates (YoY)

Revenue

-81.8%

Net Income

14.6%

EPS

29.9%

Free Cash Flow

33.0%

FY 2025 vs FY 2024

Shares & Float

Outstanding

58.8M

Float

49.9M

Free Float

84.9%

Earnings Track Record

✓

Aug 24

+2.2%

✓

Nov 24

+35.3%

✓

Mar 25

+20.0%

✗

May 25

-3.6%

✗

Aug 25

-6.9%

✓

Nov 25

+12.9%

✓

Mar 26

+33.3%

—

May 26

Beat estimates 11 of 15 quarters (73%)

About

CEO

Jay Short

Sector

Healthcare

Industry

Biotechnology

Website

Recent SEC Filings

2026-04-02

2026-03-31

2026-03-31

2026-03-23

2026-03-12

Latest BioAtla, Inc. News

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

The Motley Fool·17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

Schwab Network·18h ago

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Motley Fool·21h ago

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

The Motley Fool·21h ago

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

CNBC·23h ago

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Defense World·1d ago

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Defense World·1d ago

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL

Defense World·1d ago

Financial Summary

ExchangeNASDAQ Global Market

CIK0001826892

ISINUS09077B1044

CUSIP09077B104

Market Cap$7.7M

Beta1.065

Employees61

Phone858 558 0708

Address11085 Torreyana Road, San Diego

CountryUS

IPO Date2020-12-16

AI Summary Hub

StoxPulse AI results for BCAB: Pulse Score 48.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.

BioAtla, Inc.